title: Response of dairy cows to high doses of a sustained-release bovine somatotropin administered during two lactations. 1. Production response.
abstract: This study evaluated the effect of sometribove (zinc methionyl bST) in a sustained-release formulation administered to lactating cows at concentrations up to 3.0 g every 14 d over two lactations. Eighty-two lactating Holstein cows in their first, second, or third lactation were assigned to the study. Cows received .6, 1.8, or 3.0 g of bST in one, three, or five intramuscular injections of a unit dose (.6 g) every 2 wk. Controls received five injections of the vehicle (equivalent volume to the 3.0-g treatment) every 2 wk. Injections were administered from 60 +/- 3 d postpartum until dry-off or necropsy. Thirty-eight animals were continued on treatment for a second consecutive lactation. During the 1st yr of treatment, bST increased mean 3.5% FCM by 7.2, 9.4, and 8.4 kg/d over control production (21.1 kg/d). During the 2nd yr, milk response to .6, 1.8, and 3.0 g of bST averaged 10.6, 3.6, and 4.9 kg/d over controls (24.8 kg/d). The incidence of clinical mastitis increased in the 3.0-g group relative to controls during the 2nd yr. Thus, salable FCM averaged 8.1, 9.1, and 6.2 kg/d above controls (yr 1) and 12.1, 4.7, and -2.8 kg/d (yr 2) for the .6-, 1.8-, and 3.0-g groups. Salable FCM was unaffected by mastitis at a proposed commercial dose (.6 g). Milk fat, protein, lactose, calcium, phosphorus, zinc, magnesium, and ash concentrations were unaffected by bST treatment. Calculated energy, calcium, phosphorus, and protein balances also were unaffected except for early decreases of up to 5 Mcal/d, and 40, 20, and 600 g/d, respectively, until feed intake increased. Milk serum bST concentrations greater than the assay limit of sensitivity (1 ng/ml) were routinely measurable only at doses of 1.8 and 3.0 g. Results confirmed that bST concentrations in milk serum are exceedingly small. Overall, supraphysiological doses of sometribove increased milk production with little effect on composition. No toxic effects of bST were observed.
authors.affiliation: Monsanto Agricultural Company, Animal Sciences Division, St. Louis, MO 63198.
authors.forename: P J
authors.initials: PJ
authors.lastname: Eppard
authors.forename: S
authors.initials: S
authors.lastname: Hudson
authors.forename: W J
authors.initials: WJ
authors.lastname: Cole
authors.forename: R L
authors.initials: RL
authors.lastname: Hintz
authors.forename: G F
authors.initials: GF
authors.lastname: Hartnell
authors.forename: T W
authors.initials: TW
authors.lastname: Hunter
authors.forename: L E
authors.initials: LE
authors.lastname: Metzger
authors.forename: A R
authors.initials: AR
authors.lastname: Torkelson
authors.forename: B G
authors.initials: BG
authors.lastname: Hammond
authors.forename: R J
authors.initials: RJ
authors.lastname: Collier
mesh_terms: D000818:Animals; D002417:Cattle / Q000502:physiology*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D007774:Lactation / Q000187:drug effects*; D008892:Milk / Q000032:analysis; D008903:Minerals / Q000032:analysis; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D003692:Delayed-Action Preparations; D008903:Minerals; D011994:Recombinant Proteins; D013006:Growth Hormone